

## Hansoh Pharmaceutical Group Company Limited

## 翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)
(於開曼群島註冊成立的有限公司)
(Stock Code 股份代號: 3692)

## NOTIFICATION LETTER 通知信函

May 29, 2025

Dear Registered Shareholders,

Hansoh Pharmaceutical Group Company Limited (the "Company")

Notice of publication of Circular dated May 29, 2025 in relation to proposals for re-election of directors, general mandates to repurchase shares and to issue shares, final dividend and re-appointment of auditors together with Notice of Annual General Meeting and Proxy Form (the "Current Corporate Communications")

The English and Chinese versions of the Company's Current Corporate Communications are now available on the Company's website at www.hspharm.com and the website of The Stock Exchange of Hong Kong Limited (the "Stock Exchange") at www.hkexnews.hk respectively (the "Website Version"). The Company strongly recommends you to access the Website Version of the Current Corporate Communications and all future Corporate Communications. If you have elected to receive the Corporate Communications in printed form, the Current Corporate Communications are enclosed.

If you have difficulty in receiving email notification or gaining access to the Website Version of the Corporate Communications and would like to receive the Current Corporate Communications and all future Corporate Communications in printed form, please complete, sign the enclosed Reply Form and return it to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited ("Branch Share Registrar") at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong by post using the provided prepaid mailing label (no stamp is needed if posted in Hong Kong) or by email to 3692-ecom@vistra.com. The Company will send the Current Corporate Communications to you in printed form free of charge upon your request.

It is the responsibility of registered shareholders to provide a functional email address. If you have not provided your email address to the Company or need to update your email address, the Company recommends you to provide your email address by completing, signing the enclosed Reply Form and returning to the Branch Share Registrar at the above-mentioned address by post or by email to 3692-ecom@vistra.com. If the Company does not have your functional email address, until such time that the functional email address is provided to the Branch Share Registrar, you will be unable to receive via email notices of publication of the Website Version of Corporate Communications ("Notice of Publication") and Actionable Corporate Communications in electronic form. As such, the Company would only be able to send you the Notice of Publication and the Actionable Corporate Communications in printed form.

Should you have any queries relating to this notification, please call the Branch Share Registrar's telephone hotline at (852) 2980 1333 during business hours from 9:00 a.m. to 6:00 p.m. Monday to Friday, excluding public holidays or send an email to 3692-ecom@vistra.com.

Yours faithfully,
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Note:

Corporate Communications include any document(s) issued or to be issued by the Company for the information or action of holders of any of its securities or the investing public, including but not limited to (a) the directors' report and its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) the quarterly report, if any; (d) a notice of meeting; (e) a listing document; (f) a circular; (g) a proxy form; and (h) Actionable Corporate Communications.

Actionable Corporate Communications refer to any Corporate Communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders.

各位登記股東:

## 翰森製藥集團有限公司(「本公司」)

· 日期為2025年5月29日有關建議重選董事、購回股份及發行股份的一般授權、末期股息及續聘核數師之通函連同股東週年大會通告及代表委任書(「本次公司清訊)) 之刊發涌知

本公司的本次公司通訊之中、英文版本已分別上載於本公司網站(www.hspharm.com)及香港聯合交易所有限公司(「**聯交所**」)之網站(www.hkexnews.hk)(「**網站版本**」)。我們建議 閣下閱覽本公司本次及日後公司通訊(<sup>網註)</sup>的網站版本。如 閣下已選擇收取公司通訊的印刷本,隨函附上本次公司通訊。

如 關下因任何理由無法以電子郵件方式收取或閱覽公司通訊的網站版本及欲索取本次公司通訊及日後公司通訊的印刷本,請填妥及簽署隨附之回條,並以已預付郵費的郵寄標籤寄回本公司之香港股份過戶登記分處 (「**股份過戶登記分處**」) 卓佳證券登記有限公司 (地址為香港夏慤道16號遠東金融中心17樓) (如在香港投寄毋須貼上郵票),或電郵至3692-ecom@vistra.com。本公司會因應 閣下之要求寄上公司通訊的印刷本,費用全免。

登記股東有責任提供有效的電子郵件地址。如 閣下尚未提供 閣下之電子郵件地址予本公司,或需更新 閣下之電子郵件地址,本公司建議 閣下填妥及簽署隨附之回條,並按上述地址以郵寄方式交回本公司的股份過戶登記分處或以電郵方式發送至3692-ecom@vistra.com。如果本公司沒有收到 閣下的有效電子郵件地址, 閣下將無法透過電子郵件方式收取以電子方式發送的公司通訊網站版本的登載通知(「登載通知」)及可供採取行動的公司通訊。本 公司只能以印刷本方式向 閣下發送登載通知及可供採取行動的公司通訊之印刷本予 閣下,直至股份過戶登記分處收到 閣下有效的電子郵件地址為止。

倘 閣下對本通知有任何查詢,請致電股份過戶登記分處電話熱線(852) 2980 1333,辦公時間為星期一至五(公眾假期除外)上午9時正至下午6時正,或 電郵至3692-ecom@vistra.com。

> 翰森製藥集團有限公司 主席 鍾慧娟 謹啟

2025年5月29日

附註: 公司通訊包括本公司發佈或將予發佈以供其任何證券持有人或投資大眾參照或採取行動的任何文件,其中包括但不限於(a)董事會報告,公司年度賬目連同核數師報告以 及(如適用)財務摘要報告;(b)中期報告及(如適用)中期摘要報告;(c)季度報告(如有);(d)會議通告;(e)上市文件;(f)通函;(g)代表委任表格;及(h)可供採取行動的 公司通訊。

REPLY FORM	回條
To: Hansoh Pharmaceutical Group Company Limited (Stock Code: 3692) (the "Company") (Incorporated in the Cayman Islands with limited liability) c/o Tricor Investor Services Limited 17/F, Far East Finance Centre 16 Harcourt Road, Hong Kong	翰森製藥集團有限公司 (股份代號:3692)(「本公司」) (於開曼群島註冊成立的有限公司) 經卓佳證券登記有限公司 香港夏慤道16號 遠東金融中心17樓
Part A 目形 I/We would like to receive the Current Corporate Communication a Corporate Communications in printed form in the manner indicated b 本人/我們現欲以下列方式收取本次公司通訊及將來所有公司通訊	elow:
(Please mark "✔" in ONLY ONE of the following boxes 請從下列選擇中,僅在其中一個空格內劃上「✔」號)	
I/We would like to receive a printed copy in the English language of 本人/我們現欲收取一份英文印刷本;或	nly; OR
I/We would like to receive a printed copy in the Chinese language o 本人/我們現欲收取一份中文印刷本;或	only; OR
I/We would like to receive a printed copy in both the English langua 本人/我們現欲收取英文和中文各一份印刷本。	age and the Chinese language.
Part B Z部 I/We would like to receive all future Corporate Communications a form via the email address below: 本人/我們現欲以以下電郵地址電子郵件方式收取本公司所有將來	1
(Please provide the email address in English Capital Letters) (請以英文正楷填寫電郵地址)	
Name(s) of Shareholder(s): 股東姓名: (Please use BLOCK LETTERS 請用正楷填寫)	Signature: 簽名:
Address: 地址:	(Please use BLOCK LETTERS 請用正楷填寫)
Contact telephone number: 聯絡電話號碼:	Date: 日期:
Notes 附註:	
1. Please complete and sign this form and return it by cutting and sticking the prepaid mailing label on an envelope to the Company's branch share registrar in Hong Kong, Tricor Investor Services Limited or via email to 3692-come@vistra.com*  2. Please complete this from clearly. Any form with no indicated choice, with no signature or otherwise incorrectly completed shall be void. If your shares are held in joint names, the shareholder whose name stands first on the register of members of the Company in respect of the joint holding should sign on this form in order to be valid.  3. The above instruction for part A will apply to all future Corporate Communications to be sent to you until you notify otherwise by reasonable notice in writing to the Company (whichever its earlier). Further request in writing will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.  3. The above instruction for part A will apply to all future Corporate Communications to be sent in viring will be required if a shareholder prefers to continue receiving printed copy of future Corporate Communications.  4. Provided	
annual accounts together with a copy of the auditors' report and, where applicable, its summary internal report; (b) the internii report and, where applicable, its summary internii and, where applicable, its summary internii and, where applicable, its summary	

Mailing Label 郵寄標籤

**Tricor Investor Services Limited** 卓佳證券登記有限公司 Freepost No. 簡便回郵號碼: 10 GPO

閣下寄回本回條時,請將郵寄標籤剪貼於信封上。 如在本港投寄, 閣下無需支付郵費或貼上郵票。

Please cut the mailing label and stick it on an envelope to return this Reply Form to us.



Hong Kong香港

"Personal Data" in this statement has the same meaning as "personal data" defined in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO"). Your supply of the Personal Data is on a voluntary basis and for the purpose of processing your instructions as stated in this form (the "Purposes"). If you fail to supply sufficient information, the Company may not be able to process your instructions. The Company may disclose or transfer the Personal Data to its subsidiaries, its share register and/or third party service provides administrative, computer and other services to the Company for use in connection with the Purposes and to such parties who law to request the information or are otherwise relevant for the Purposes and need to receive the information. The Personal Data will be relationed for such personal Data to its subsidiaries, its share register and/or third party service provides administrative, computer and other services to the Company for use in connection with the Purposes and to such parties who play law to request the information or are otherwise relevant for the Purposes and need to receive the information. The Personal Data will be relationed to such personal Data to its subsidiaries, its share register and/or third purposes, but the information of any otherwise relevant for the Purposes and need to receive the information. The Personal Data will be relationed to such personal Data to its subsidiaries, its share register and/or third purposes, and to such parties with a such purposes, and to such parties with a such purposes, and to such purposes, the purposes and need to receive the information. The Personal Data will be relationed to the purposes and need to receive the information. The Personal Data will be relationed to the purposes and need to receive the information. The Personal Data will be relationed to the purposes and to such purposes, the information of any other purposes, the information and receive the information. The Personal Data will be relationed to s